CASTLE was a 96-week study comparing efficacy and safety in treatment-naive HIV-1-infected patients randomized to atazanavir/ritonavir ( ATV/r ) versus lopinavir/ritonavir ( LPV/r ) , each in combination with tenofovir disoproxil fumarate/emtricitabine .